Alkermes

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alkermes and other ETFs, options, and stocks.

About ALKS

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. 

CEO
Richard F. Pops
CEORichard F. Pops
Employees
2,050
Employees2,050
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2011
Founded2011
Employees
2,050
Employees2,050

ALKS Key Statistics

Market cap
4.66B
Market cap4.66B
Price-Earnings ratio
19.39
Price-Earnings ratio19.39
Dividend yield
Dividend yield
Average volume
2.22M
Average volume2.22M
High today
$28.02
High today$28.02
Low today
$27.03
Low today$27.03
Open price
$27.43
Open price$27.43
Volume
1.75M
Volume1.75M
52 Week high
$36.32
52 Week high$36.32
52 Week low
$25.17
52 Week low$25.17

Stock Snapshot

The current Alkermes(ALKS) stock price is $27.97, with a market capitalization of 4.66B. The stock trades at a price-to-earnings (P/E) ratio of 19.39.

On 2026-03-12, Alkermes(ALKS) stock traded between a low of $27.03 and a high of $28.02. Shares are currently priced at $27.97, which is +3.5% above the low and -0.2% below the high.

The Alkermes(ALKS)'s current trading volume is 1.75M, compared to an average daily volume of 2.22M.

During the past year, Alkermes(ALKS) stock moved between $25.17 at its lowest and $36.32 at its peak.

During the past year, Alkermes(ALKS) stock moved between $25.17 at its lowest and $36.32 at its peak.

ALKS News

Simply Wall St 9h
Is Alkermes Offering Value After Recent Share Price Weakness And DCF Upside Signals

If you are wondering whether Alkermes at around US$27.77 is offering genuine value or just looks cheap on the surface, you are in the right place. The share pr...

Is Alkermes Offering Value After Recent Share Price Weakness And DCF Upside Signals
Simply Wall St 4d
Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case?

Alkermes plc recently reported that fourth‑quarter 2025 revenue slipped to US$384.55 million, with net income and earnings per share also lower year over year,...

Is Alkermes’ Slower Q4 and CEO Transition Reshaping Its Orexin Strategy and Investment Case?
TipRanks 6d
Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch

Alkermes plc (ALKS) announced an update on their ongoing clinical study. The Brilliance NT1 Study 302 is a Phase 3 trial run by Alkermes, Inc. to test ALKS 268...

Analyst ratings

82%

of 17 ratings
Buy
82.4%
Hold
17.6%
Sell
0%

People also own

Based on the portfolios of people who own ALKS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.